HC Wainwright & Co. Maintains Buy on Black Diamond Therapeutic, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Black Diamond Therapeutic (NASDAQ: BDTX) but has lowered the price target from $12 to $11.
May 16, 2024 | 11:36 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained its Buy rating on Black Diamond Therapeutic but has lowered the price target from $12 to $11.
The maintained Buy rating suggests continued confidence in the stock, but the lowered price target indicates a slightly less optimistic outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100